CDH1 and prostate carcinoma: A study reported that miR-N5 targets the 3’-UTR of CREBBP to suppress its expression, which in turn mediates H3K56 acetylation in the promoter regions of EGFR, β-catenin, and CDH1 in prostate cancer [42].